Landmark CoMMpass Study data now available through MMRF Researcher Gateway

Unique public access to patient-level biomarker and clinical data from landmark longitudinal study of people diagnosed with multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) announced today that new data from the landmark CoMMpass Study™ is now available to researchers via the MMRF's Researcher Gateway, an online, open-access portal designed to make key genomic and clinical data publically available for additional study.

The Gateway provides access to clinical and molecular data for myeloma that has not been previously captured, including baseline bone marrow and blood samples; correlating clinical data; treatments and responses; quality of life data and extensive molecular profiling. Genomic data from 92 patients and clinical data from 292 patients enrolled in the CoMMpass Study is now available.

"We are committed to facilitating the open and rapid communication of scientific findings resulting from our clinical genomics research," said Dr. Fiona An, Senior Vice President for Clinical Development of MMRF. "Multiple myeloma is an extremely complex and heterogeneous disease. By centralizing this data and sharing it with researchers worldwide, MMRF is helping to accelerate the discovery of individualized treatment approaches, biomarkers, diagnostics and new drug targets for people diagnosed with multiple myeloma."

CoMMpass is a longitudinal study of patients with newly-diagnosed active multiple myeloma. The goal is to map the genomic profile of each patient to clinical outcomes to develop a more complete understanding of patient responses to treatments. A cornerstone of the MMRF's Personalized Medicine Initiative, the study will collect and analyze tissue samples and genetic information from approximately 1,000 newly diagnosed multiple myeloma patients for at least eight years.

The MMRF Researcher Gateway shares data from the CoMMpass Study that is designed to show what treatments are used most often as first and subsequent lines of therapy, and to correlate this information with critical therapeutic response criteria including best responses achieved, overall survival, time to disease progression and quality of life measures. It is also powered to track treatment data to correspond with genetic information such as mutations and translocations (the movement of a chromosomal segment from one position to another, a phenomenon that often occurs in cancer). Researchers who access the MMRF Researcher Gateway can combine and analyze this information in different cohorts of their choosing, as well as share their findings with colleagues in the same or other centers, for collaboration worldwide.

"The open availability of the data to researchers fosters the development of novel hypotheses about the disease, encourages valuable analyses and offers new ways for researchers to evaluate treatment efficacy in different patient populations over time, among other variables," said Dr. An.

Source: Feinstein Kean Healthcare